Affinage

ZMYND10

Zinc finger MYND domain-containing protein 10 · UniProt O75800

Length
440 aa
Mass
50.3 kDa
Annotated
2026-06-11
76 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ZMYND10 is a cytoplasmic factor essential for the pre-assembly of axonemal dynein arms that power motile cilia and flagella, and its loss causes primary ciliary dyskinesia through complete loss of ciliary motility (PMID:23891471, PMID:29916806). Mechanistically, ZMYND10 acts as a co-chaperone that confers specificity of the FKBP8–HSP90 chaperone complex toward axonemal dynein heavy chain clients; loss of ZMYND10 destabilizes these clients and triggers broader degradation of dynein motor subunits, and pharmacological FKBP8 inhibition phenocopies this instability (PMID:29916806). During cytoplasmic pre-assembly, ZMYND10 stabilizes the outer dynein arm intermediate chain DNAI1, which in turn stabilizes DNAI2, and it physically associates with dynein assembly factors LRRC6, DYX1C1, and C21ORF59 (PMID:29601588). The interaction with LRRC6 is mediated by the LRRC6 CS domain and the ZMYND10 C-terminal domain, and disease-causing mutations in either protein abrogate this binding; ZMYND10 colocalizes with centriolar markers and its loss eliminates axonemal DNAH5 and DNALI1 from cilia while leaving the 9+2 axoneme structurally intact, defining a pre-assembly rather than structural role (PMID:23891469, PMID:29601588). Beyond dynein assembly, ZMYND10 promotes centriole amplification and multiciliogenesis through transcriptional activation of the E2f4 promoter, which regulates Deup1 expression (PMID:41413096). A separate body of work characterizes ZMYND10/BLU as an epigenetically silenced 3p21.3 tumor suppressor whose re-expression arrests the cell cycle and suppresses tumorigenicity across nasopharyngeal, gastric, and breast cancer models (PMID:15122337, PMID:16929489, PMID:26043875).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2013 High

    Established ZMYND10 as a PCD gene and defined its first molecular partnership, answering whether and how a previously uncharacterized protein contributes to cilia motility.

    Evidence Biallelic mutation identification in PCD families, EM ultrastructure showing dual dynein arm loss, reciprocal Co-IP mapping ZMYND10–LRRC6 interaction domains, and model-organism knockdowns (zebrafish, Xenopus, Drosophila)

    PMID:23891469 PMID:23891471

    Open questions at the time
    • Did not resolve the biochemical activity of ZMYND10 (chaperone vs structural)
    • Mechanism by which LRRC6 binding supports dynein assembly unresolved
    • Did not identify the specific dynein clients stabilized
  2. 2018 High

    Resolved the biochemical function of ZMYND10 as a co-chaperone and ordered its action on specific dynein subunits, explaining why its loss causes broad dynein motor degradation.

    Evidence Zmynd10 knockout mice with quantitative proteomics, pharmacological FKBP8 inhibition phenocopy, Co-IP interaction mapping, and co-expression stability assays demonstrating DNAI1→DNAI2 stabilization hierarchy

    PMID:29601588 PMID:29916806

    Open questions at the time
    • Structural basis of FKBP8–HSP90–ZMYND10–client assembly not determined
    • How ZMYND10 selects dynein heavy chain clients unknown
    • Order of recruitment relative to LRRC6/DYX1C1/C21ORF59 not fully resolved
  3. 2017 Medium

    Confirmed conserved dynein-assembly function across species and probed the contribution of the MYND zinc finger domain.

    Evidence Medaka morpholino knockdown and TALEN knockout with EM, high-speed video microscopy, and truncation-mutant rescue showing partial activity without zf-MYND

    PMID:28823919

    Open questions at the time
    • Domain contributions only partially mapped
    • Did not define which dynein arms require which domains
  4. 2020 Low

    Extended ZMYND10 ciliary roles beyond dynein assembly, raising the question of involvement in intraflagellar transport and spinal development.

    Evidence Paramecium RNAi with IFT43 localization analysis; zebrafish CRISPR knockout recapitulating scoliosis with AIS-cohort exome variants

    PMID:33251213 PMID:33279757

    Open questions at the time
    • IFT involvement is correlative localization without direct mechanistic placement
    • Scoliosis link not mechanistically connected to dynein function
    • Single-lab/single-organism observations
  5. 2004 Medium

    Identified BLU/ZMYND10 as an epigenetically regulated locus with tumor-suppressive activity, opening a parallel cancer-biology line of inquiry.

    Evidence Promoter reporter and E2F binding analysis, methylation-specific PCR, demethylation rescue, and colony formation assays

    PMID:15122337

    Open questions at the time
    • Mechanism of growth suppression not defined at this stage
    • Relationship between ciliary and tumor-suppressor functions unaddressed
  6. 2006 Medium

    Provided causal in vivo evidence that BLU/ZMYND10 suppresses tumor formation, distinguishing it from a mere correlate of methylation.

    Evidence Tetracycline-regulated gene inactivation in nude mouse NPC xenografts showing tumor formation restored upon BLU downregulation

    PMID:16929489

    Open questions at the time
    • Downstream effector pathway not identified
    • Single tumor type
  7. 2012 Medium

    Connected BLU/ZMYND10 to specific growth-control signaling, building a mechanistic basis for its tumor-suppressor activity.

    Evidence Co-IP/domain mapping of BLU–sMEK1 interaction with apoptosis assays; adenoviral re-expression with cell cycle analysis, JNK/cyclin D1 reporter assays, and c-Jun phosphorylation immunoblotting

    PMID:22349239 PMID:22727408

    Open questions at the time
    • sMEK1 interaction not reciprocally validated in vivo
    • Multiple proposed pathways (JNK, PP4) not unified
    • Link to the chaperone function unclear
  8. 2015 Medium

    Defined the transcriptional control of BLU and its loss in cancer, linking single-CpG methylation to Sp1-dependent silencing and proliferation.

    Evidence Bisulfite sequencing, ChIP, EMSA, luciferase reporter, and siRNA knockdown with colony formation in gastric cancer cells; CTCF insulator characterization at the 3p21.3 BLU/RASSF1A locus by EMSA, ChIP, and bisulfite sequencing

    PMID:20877461 PMID:26043875

    Open questions at the time
    • Causal contribution of -39 CpG methylation in primary tumors not established
    • Interplay between CTCF insulator loss and BLU silencing in vivo unresolved
  9. 2019 Medium

    Extended tumor-suppressor mechanism to additional pathways (angiogenesis and miRNA-mediated effector control) in further cancer models.

    Evidence Ectopic expression with VEGF/TSP1 PCR array, ELISA, tube formation and matrigel plug angiogenesis assays; miR145-5p/NEDD9 3'-UTR luciferase validation with migration/invasion and xenograft assays

    PMID:25347745 PMID:31801619

    Open questions at the time
    • Mechanisms operate through different effectors without unification
    • Direct molecular target of ZMYND10 in these axes not defined
  10. 2025 Medium

    Established a transcriptional role for Zmynd10 in centriole amplification and multiciliogenesis, expanding its ciliary function beyond cytoplasmic dynein pre-assembly.

    Evidence siRNA knockdown in mouse ependymal cells, E2f4 promoter-luciferase reporter, E2f4 knockdown epistasis, and RT-qPCR/immunoblotting for E2f4 and Deup1

    PMID:41413096

    Open questions at the time
    • How a cytoplasmic co-chaperone activates E2f4 transcription is mechanistically unexplained
    • Direct DNA binding vs indirect regulation not distinguished
    • Single lab/cell type

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ZMYND10's cytoplasmic dynein-chaperone function, its proposed transcriptional/tumor-suppressor activities, and its multiciliogenesis role mechanistically integrate into a single protein remains unresolved.
  • No structural model of ZMYND10 in the FKBP8–HSP90–dynein assembly complex
  • Mechanism linking a cytoplasmic co-chaperone to nuclear/transcriptional outputs (E2f4, Sp1, tumor suppression) undefined
  • Whether ciliary and cancer phenotypes share a common molecular activity unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 2 GO:0044183 protein folding chaperone 1 GO:0140313 molecular sequestering activity 1
Localization
GO:0005829 cytosol 2 GO:0005815 microtubule organizing center 1
Partners
C21ORF59DNAI1DYX1C1FKBP8LRRC6SMEK1
Complex memberships
FKBP8-HSP90 chaperone complex

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2013 ZMYND10 protein physically interacts with LRRC6 via the LRRC6 CS domain and the ZMYND10 C-terminal domain; certain disease-causing mutations in either protein abrogate this interaction. Both proteins colocalize with centriole markers SAS6 and PCM1. Loss of ZMYND10 results in absence of axonemal dynein components DNAH5 and DNALI1 from respiratory cilia. Co-immunoprecipitation, immunofluorescence colocalization with centriole markers, whole-exome resequencing, zebrafish zmynd10 morpholino knockdown (ciliary paralysis, cystic kidneys, otolith defects), Xenopus knockdown (ciliogenesis defect) American journal of human genetics High 23891469
2013 ZMYND10 (BLU) is a cytoplasmic protein required for assembly of both inner dynein arms (IDAs) and outer dynein arms (ODAs) in motile cilia/flagella. Loss-of-function mutations cause complete cilia immotility and dual dynein arm loss at the ultrastructural level. The MYND-type zinc finger domain is important for function. Human ZMYND10 interacts with LRRC6 in the cytoplasm. Biallelic mutation identification in PCD families, immunofluorescence/electron microscopy of ciliary axonemes, Drosophila P-element gene silencing (IDA and ODA defects, proprioception deficit, male sterility), tagged protein localization, Co-IP with LRRC6, missense rescue experiments in Drosophila American journal of human genetics High 23891471
2018 ZMYND10 acts as a novel co-chaperone that confers specificity of the FKBP8-HSP90 chaperone complex towards axonemal dynein heavy chain clients required for cilia motility. Loss of ZMYND10 perturbs chaperoning of axonemal dynein heavy chains, triggering broader degradation of dynein motor subunits. Pharmacological inhibition of FKBP8 phenocopies dynein motor instability associated with ZMYND10 loss. Human disease-causing ZMYND10 variants disrupt its ability to act as an FKBP8-HSP90 co-chaperone. Mouse genetics (Zmynd10 knockout), quantitative proteomics, imaging, pharmacological FKBP8 inhibition in airway cells, functional analysis of disease-causing variants eLife High 29916806
2018 ZMYND10 stabilizes ODA intermediate chain protein DNAI1 during cytoplasmic pre-assembly of dynein arms; ZMYND10 interacts with ODA components and other dynein assembly factors (LRRC6, DYX1C1, C21ORF59). Stabilization of DNAI1 by ZMYND10 subsequently stabilizes DNAI2. Levels of these co-assembly proteins are significantly reduced in Zmynd10-/- mice. The 9+2 axoneme structure is normal in Zmynd10-/- mice, indicating a specific pre-assembly function rather than structural role. Zmynd10-/- mouse model, co-immunoprecipitation, co-expression stability assays, immunofluorescence, electron microscopy of cilia PLoS genetics High 29601588
2017 In medaka fish, zmynd10 is exclusively expressed in cells with motile cilia; morpholino knockdown causes loss of outer dynein arms and ciliary immotility affecting left-right axis determination. The C-terminal MYND-type zinc finger domain is important but not exclusively required for function, as a truncated protein lacking zf-MYND retained partial activity in rescue experiments. Zmynd10 knockout adult fish exhibit sperm dysmotility, scoliosis, and progressive polycystic kidney. Morpholino knockdown, TALEN knockout, transmission electron microscopy, rescue experiments with truncation mutants, high-speed video microscopy Developmental biology Medium 28823919
2004 The BLU (ZMYND10) promoter is activated by environmental stresses such as heat shock and is regulated by the transcription factor E2F. The promoter and first exon are located within a CpG island. Promoter hypermethylation causes silencing, which can be reversed by 5-aza-2'-deoxycytidine treatment. Ectopic BLU expression inhibits colony formation of cancer cells, consistent with tumor suppressor activity. Promoter reporter assays, methylation-specific PCR, 5-aza-2'-deoxycytidine demethylation, colony formation assay, E2F binding analysis Oncogene Medium 15122337
2006 BLU/ZMYND10 functionally suppresses tumor formation in vivo when expressed in NPC cells implanted in nude mice; doxycycline-mediated downregulation of BLU in these tumor-suppressive clones restores tumor formation ability, providing direct causal evidence for its tumor suppressor function. Gene inactivation test (GIT) with tetracycline-regulated expression system, nude mouse xenograft assay International journal of cancer Medium 16929489
2012 BLU (ZMYND10) directly interacts with sMEK1 (a regulatory subunit of protein phosphatase 4) via its N-terminal domain binding to the C-terminal domain of sMEK1. This interaction increases sMEK1 expression and induces pro-apoptotic activity. Co-immunoprecipitation, domain mapping by deletion constructs, apoptosis assays Cellular signalling Medium 22349239
2012 BLU/ZMYND10 re-expression in NPC cells inhibits clonogenic growth, arrests cell cycle at G1 phase, downregulates JNK activity, inhibits cyclin D1 promoter activity, and reduces phosphorylation of c-Jun. Adenoviral BLU re-expression, flow cytometry cell cycle analysis, reporter gene assay for JNK and cyclin D1 promoter activities, immunoblotting for c-Jun phosphorylation BMC cancer Medium 22727408
2014 BLU/ZMYND10 overexpression in NPC cells suppresses VEGF165, VEGF189, and TSP1 expression at RNA and protein levels, reduces secreted VEGF, and inhibits cellular invasion, migration, and tube formation in vitro. In vivo, BLU expression inhibits tumor growth and suppresses angiogenesis in matrigel plug assays. PCR array, stable transfection, ELISA for secreted VEGF, invasion/migration assay, tube formation assay, nude mouse xenograft and matrigel plug angiogenesis assay Oncogene Medium 25347745
2018 BLU/ZMYND10 inhibits ERK signaling by reducing protein substrate phosphorylation, inhibiting Elk reporter activity, and blocking cyclin D1 (CCND1) promoter activity, thereby arresting cell cycle at G1. BLU antagonizes the effect of HRAS V12G on ERK activation and cyclin D1/B1 promoter activities. Xenograft tumor injection with BLU-expressing adenovirus, reporter gene co-transfection, phosphorylation immunoblotting, FACS cell cycle analysis International journal of clinical and experimental pathology Low 31938097
2015 BLU promoter activity is regulated by transcription factor Sp1; methylation of the -39 CpG site in the BLU proximal promoter directly prevents Sp1 binding and reduces transcriptional activity by ~70%. Knockdown of BLU promotes cellular proliferation and colony formation in gastric cancer cells. Bisulfite sequencing, ChIP, EMSA, luciferase reporter assay, siRNA knockdown, colony formation assay International journal of oncology Medium 26043875
2019 ZMYND10 suppresses breast cancer tumorigenicity through a miR145-5p/NEDD9 signaling axis: ectopic ZMYND10 expression enhances miR145-5p expression, which suppresses NEDD9 protein by targeting its 3'-UTR, leading to reduced cell migration, invasion, and xenograft tumor growth. Ectopic expression in breast cancer cell lines, luciferase 3'-UTR reporter assay, migration/invasion assays, xenograft tumor growth in vivo Clinical epigenetics Medium 31801619
2010 A CTCF-binding insulator located between the tandem BLU and RASSF1A genes at 3p21.3 creates distinct epigenetic domains, providing a barrier between the two gene loci. In normal cells, distinct methylation and chromatin boundaries are separated by the CTCF binding domains; in cancer cells, these boundaries are lost. Treatment with demethylation reagent or HDAC inhibitor restores CTCF binding and barrier effect. Gel shift assay (EMSA), ChIP-PCR, methylation-specific oligonucleotide array, bisulfite sequencing, pharmacological treatments PloS one Medium 20877461
2020 In zebrafish, CRISPR/Cas9 knockout of zmynd10 recapitulates scoliosis in viable adult fish, and coding variants in zmynd10 identified by whole-exome sequencing are associated with adolescent idiopathic scoliosis susceptibility, linking zmynd10 dynein assembly factor function to spinal curvature. CRISPR/Cas9 knockout in zebrafish, whole-exome sequencing of AIS patient cohort Frontiers in cell and developmental biology Low 33251213
2020 In Paramecium tetraurelia, RNAi depletion of ZMYND10 causes severe ciliary defects and abnormal localization of the intraflagellar transport protein IFT43 along cilia, suggesting ZMYND10 is involved in regulating IFT in addition to dynein arm assembly. RNAi knockdown in Paramecium, immunofluorescence localization of IFT43, swimming behavior assay European journal of protistology Low 33279757
2017 BLU/ZMYND10 re-expression promotes TRAIL-induced apoptosis in NPC cells by inhibiting the NF-κB pathway, as evidenced by reduced IKKα, p65 NF-κB, and NF-κB-induced anti-apoptotic factors cFLIPL and cIAP2, along with enhanced caspase-8 cleavage. Recombinant adenoviral BLU infection, NF-κB reporter assay, FACS-based TMRE/annexin V assays, immunoblotting for NF-κB pathway components Oncotarget Low 28029652
2025 Zmynd10 drives centriole amplification and multiciliogenesis through transcriptional activation of the E2f4 promoter, which in turn regulates Deup1 expression; knockdown of Zmynd10 in mouse ependymal cells reduces ciliary density and downregulates E2f4 and Deup1 at mRNA and protein levels. Zmynd10 siRNA knockdown in mouse ependymal cells (mEPCs), E2f4 promoter-luciferase reporter assay, E2f4 siRNA knockdown, RT-qPCR and immunoblotting Scientific reports Medium 41413096

Source papers

Stage 0 corpus · 76 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer discovery 376 30257958
2018 Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer discovery 326 29657135
2019 First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery 216 31575541
2013 ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6. American journal of human genetics 154 23891469
2022 Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. Journal of medicinal chemistry 131 35838760
2013 Mutations in ZMYND10, a gene essential for proper axonemal assembly of inner and outer dynein arms in humans and flies, cause primary ciliary dyskinesia. American journal of human genetics 130 23891471
2004 The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 115 15122337
2004 Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 104 14743209
2003 Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 82 12629521
2019 BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulmonary pharmacology & therapeutics 81 30902655
2004 Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer letters 63 15922865
2003 Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. International journal of cancer 54 12794757
2018 ZMYND10 functions in a chaperone relay during axonemal dynein assembly. eLife 49 29916806
2005 Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. International journal of cancer 48 15540210
2019 Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British journal of haematology 45 31309543
2008 RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain pathology (Zurich, Switzerland) 44 18616639
2018 ZMYND10 stabilizes intermediate chain proteins in the cytoplasmic pre-assembly of dynein arms. PLoS genetics 43 29601588
2006 Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. International journal of cancer 41 16929489
2017 A label-free nanostructured plasmonic biosensor based on Blu-ray discs with integrated microfluidics for sensitive biodetection. Biosensors & bioelectronics 37 28501746
2014 Quantification of rolling circle amplified DNA using magnetic nanobeads and a Blu-ray optical pick-up unit. Biosensors & bioelectronics 37 25453736
2006 Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecologic oncology 35 17097722
2018 Hacking CD/DVD/Blu-ray for Biosensing. ACS sensors 30 29978699
2008 Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer research 30 18751390
2006 Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer letters 28 15885884
2023 A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma. Investigational new drugs 27 36763233
2017 BLU-285, DCC-2618 Show Activity against GIST. Cancer discovery 22 28077435
2025 Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer research 20 39945650
2024 BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer. Therapeutic advances in medical oncology 20 39444426
2022 Blood-Coated Sensor for High-Throughput Ptychographic Cytometry on a Blu-ray Disc. ACS sensors 20 35393855
2019 ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer. Clinical epigenetics 20 31801619
1990 Lung tumorigenicity of benzene oxide, benzene dihydrodiols and benzene diolepoxides in the BLU:Ha newborn mouse assay. Carcinogenesis 19 2401039
2020 Coding Variants Coupled With Rapid Modeling in Zebrafish Implicate Dynein Genes, dnaaf1 and zmynd10, as Adolescent Idiopathic Scoliosis Candidate Genes. Frontiers in cell and developmental biology 18 33251213
2017 Loss of zinc finger MYND-type containing 10 (zmynd10) affects cilia integrity and axonemal localization of dynein arms, resulting in ciliary dysmotility, polycystic kidney and scoliosis in medaka (Oryzias latipes). Developmental biology 18 28823919
2015 Blu-ray based optomagnetic aptasensor for detection of small molecules. Biosensors & bioelectronics 18 26342583
2012 Tumor suppressor BLU enhances pro-apoptotic activity of sMEK1 through physical interaction. Cellular signalling 17 22349239
2012 Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC cancer 17 22727408
2024 An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva. Science translational medicine 16 38809966
2025 Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer research 15 39945638
2013 Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis. Biochemical and biophysical research communications 15 23628417
2016 ZMYND10--Mutation Analysis in Slavic Patients with Primary Ciliary Dyskinesia. PloS one 13 26824761
2010 Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A. PloS one 13 20877461
2016 Blu-ray Technology-Based Quantitative Assays for Cardiac Markers: From Disc Activation to Multiplex Detection. Analytical chemistry 12 27268387
2014 Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma. Oncogene 12 25347745
2019 Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 11 30802754
2022 BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro. Biochemical and biophysical research communications 8 35093636
2017 Tumor suppressor BLU promotes TRAIL-induced apoptosis by downregulating NF-κB signaling in nasopharyngeal carcinoma. Oncotarget 8 28029652
2013 BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. The international journal of biochemistry & cell biology 8 23579097
2019 P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International journal of pharmaceutics 7 31759109
2020 Primary ciliary dyskinesia relative protein ZMYND10 is involved in regulating ciliary function and intraflagellar transport in Paramecium tetraurelia. European journal of protistology 6 33279757
2019 Blu-Ray Discs as Universal Biochip Substrates: Lithography-Free Surface Activation and Assay Patterning. ACS applied materials & interfaces 6 31525871
2015 Inactivation of BLU is associated with methylation of Sp1-binding site of BLU promoter in gastric cancer. International journal of oncology 6 26043875
2010 High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer investigation 6 20394502
2022 Gold nanoparticle decorated blu-ray digital versatile disc as a highly reproducible surface-enhanced Raman scattering substrate for detection and analysis of rotavirus RNA in laboratory environment. Journal of biophotonics 5 36054627
2013 Photoattachment of thiolated DNA probes on SU-8 spin-coated Blu-ray disk surfaces for biosensing. Journal of materials chemistry. B 5 32261697
2012 Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome. Journal of cancer research and clinical oncology 5 22246278
2014 Position-addressable digital laser scanning point fluorescence microscopy with a Blu-ray disk pickup head. Biomedical optics express 4 24575338
2003 [Analysis of suppressive roles of BLU gene at 3p21.3 in nasopharyngeal carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer 4 12600284
2026 CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nature communications 3 41571637
2025 Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945. NPJ precision oncology 3 40836025
2024 Sodium arsenite impairs sperm quality via downregulating the ZMYND15 and ZMYND10. Environmental toxicology 3 38798119
2018 BLU-667 Targets RET-Altered Cancers. Cancer discovery 3 29657136
2018 Tumor suppressor BLU exerts growth inhibition by blocking ERK signaling and disrupting cell cycle progression through RAS pathway interference. International journal of clinical and experimental pathology 3 31938097
1995 Tissue distribution of DNA adducts in pre-weanling BLU:Ha mice treated with a tumorigenic dose of fluoranthene. Cancer letters 3 7757965
1992 Hybridization relatedness of Israeli and U.S. bluetongue (BLU) serotypes using cDNA probes from BLU virus strain 11-UC8. Archives of virology 3 1309643
2013 Blu-ray disk lens as the objective of a miniaturized two-photon fluorescence microscope. Optics express 2 24514733
2007 The blu Blur: mutation of a vesicular glutamate transporter reduces the resolution of zebrafish vision. Neuron 1 17196524
2026 Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST. Journal of medicinal chemistry 0 41807293
2026 Benzo[a]pyrene lowers the sperm quality in male rats by downregulating the expression of ZMYND15 and ZMYND10. Reproductive toxicology (Elmsford, N.Y.) 0 41850444
2026 BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations. Molecular cancer therapeutics 0 42126003
2026 A homozygous splice-site variant in ZMYND10 causes primary ciliary dyskinesia with primary infertility in a Chinese family. Frontiers in medicine 0 42180707
2025 AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors. Journal of experimental & clinical cancer research : CR 0 40405293
2025 Molecular Insights into Outer Dynein Arm Defects in Primary Ciliary Dyskinesia: Involvement of ZMYND10 and GRP78. Cells 0 40558543
2025 The fourth-generation EGFR tyrosine kinase inhibitor BLU-945 resensitizes ABCG2-overexpressing multidrug-resistant non-small cell lung cancer cells to cytotoxic anticancer drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 0 41120063
2025 Zmynd10 drives centriole biogenesis and multiciliogenesis through the transcriptional regulation of E2f4. Scientific reports 0 41413096
2022 Silencing of ciliary protein ZMYND10 affects amitotic macronucleus division in Paramecium tetraurelia. European journal of protistology 0 35065333
2003 [Hypermethylation status of blu gene in nasopharyngeal lymphoma]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 0 12697125

Missed literature

Know a paper Affinage missed for ZMYND10? Flag it for the maintainers and the community.

No submissions yet.